Health & Medicine

STAT+: Pharmalittle: We're reading about a Trump deal with Regeneron, reclassifying medical marijuana, and more

alinemati1983-69871 day ago

27 sec read2 views0 listens

President Trump announced a drug-pricing agreement with Regeneron Pharmaceuticals, reducing prices on drugs for Medicaid and making cholesterol medicine more affordable, while also reclassifying state-licensed medical marijuana as less dangerous. This matters as it impacts healthcare costs and research opportunities in pharmaceuticals, potentially lowering barriers to cannabis studies. Watch for how this policy shift influences future drug pricing negotiations and medical cannabis regulations.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

alinemati1983-6987Written by alinemati1983-6987

View all posts

Health & MedicineApr 625 sec read

What the peptide craze reveals about Americans' relationship with risk

Robert F. Kennedy Jr., despite advocating for natural health choices, supports the use of experimental peptides, which are gaining popularity despite lacking sufficient study on their efficacy and safety. This trend highlights a significant risk in s...

Ali Nemati

Health & MedicineFeb 2526 sec read

STAT+: How Mayo Clinic's patients are helping Merck train its AI

Mayo Clinic's patient data is being used by Merck to train its AI systems for better prognosis outcomes, highlighting a significant collaboration between healthcare providers and pharmaceutical companies in leveraging AI. This partnership underscores...

Ali Nemati

Health & MedicineMar 1833 sec read

STAT+: How a Texas couple is getting rich off out-of-network medical bills

A Texas couple, Alla and Scott LaRoque, have amassed significant wealth by leveraging a federal arbitration process through their company HaloMD, which helps healthcare providers dispute bills with insurance companies; however, this strategy is under...

Ali Nemati

Health & MedicineMar 1228 sec read

STAT+: The FDA is targeting telehealth marketing of GLP-1 drugs. Who's prescribing them?

The FDA is targeting telehealth companies for misleading marketing of compounded GLP-1 weight loss drugs, warning them against implying FDA approval. The crackdown also implicates affiliated medical groups that prescribe these unapproved medications,...

Ali Nemati

Health & MedicineMar 1128 sec read

STAT+: A top biotech VC quietly helped Epstein's 'great friend' make a comeback

Despite Boris Nikolic's tarnished reputation due to his association with Jeffrey Epstein, venture capitalist Alexis Borisy helped him raise over $100 million for a new fund through Curie.Bio, facilitating Nikolic’s comeback in the biotech industry. T...

Ali Nemati

STAT+: Pharmalittle: We're reading about a Trump deal with Regeneron, reclassifying medical marijuana, and more

Related Articles

What the peptide craze reveals about Americans' relationship with risk

STAT+: How Mayo Clinic's patients are helping Merck train its AI

STAT+: How a Texas couple is getting rich off out-of-network medical bills

STAT+: The FDA is targeting telehealth marketing of GLP-1 drugs. Who's prescribing them?

STAT+: A top biotech VC quietly helped Epstein's 'great friend' make a comeback